• Intended for patients who meet Hereditary Breast and Ovarian Cancer (HBOC) syndrome or Lynch syndrome (LS) criteria
  • Doubles the positive rate for clinically actionable mutations compared to single syndrome testing1
  • Results in similar costs and healthcare utilization without increasing healthcare costs2

    Fact Sheets and Product Info:

    Executive Summary Download PDF
    Cancer Gene Table View Table
    Tech Specifications Tech Specifications


    About Hereditary Cancer:

    Multiple genes can be associated with a single cancer. Multiple cancer risks can be associated with a single gene.

    It is now recognized through an increasing amount of published literature that the same type of cancer or family history of cancer can be caused by mutations in different genes. As well, the characteristics of one hereditary cancer syndrome can overlap with those of another syndrome. With the technological advances in molecular diagnostics, testing for these additional genes can be performed simultaneously with BRCA1 and BRCA2.


    About MyRisk:

    MyRisk is proven to increase the identification of mutation carriers within the same National Comprehensive Cancer Network® recommended testing population.

    One key feature is the test result that providers and patients receive. Instead of a test result indicating only whether the patient is positive or negative for a gene mutation, the MyRisk test provides a clinical decision support tool. This tool outlines patients’ cancer risks and the medical management recommendations endorsed by societal guidelines.


    1. Rosenthal, E, et al. Cancer Genet. 2017 Dec;218-219:58-68.
    2. Byfield, SD, et al. J Comp Eff Res. 2021 Feb;10(3):207-217.

    Myriad Products